F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study
Purpose: The assessment of gliomas by 18F-FDOPA PET imaging in adjunct to MRI showed high performance by combining static and dynamic features to non-invasively predict the isocitrate dehydrogenase (IDH) mutations and the 1p/19q co-deletion, which the World Health Organization classified as significant parameters in 2016.
The current study evaluates whether other 18F-FDOPA PET radiomics features further improve performance and the contributions of each of these features to performance.
Methods: Our study included seventy-two, retrospectively selected, newly diagnosed, glioma patients with F-FDOPA PET dynamic acquisitions. A set of 114 features, including conventional static features and dynamic features as well as other radiomics features were extracted and machine-learning models trained to predict IDH mutations and the 1p/19q co-deletion.
Models were based on a machine-learning algorithm built from stable, relevant, and uncorrelated features selected by hierarchical clustering followed by a bootstrapped feature selection process. Models were assessed by comparing area under the curve (AUC) using a nested cross-validation approach. Feature importance was assessed using SHapley Additive exPlanations (SHAP) values.
Results: The best models were able to predict IDH mutations (logistic regression with L2 regularization) and the 1p/19q co-deletion (support vector machine with radial basis function kernel) with an AUC of 0.831[0.790;0.873] and 0.724[0.669;0.782] respectively.
For the prediction of IDH mutations, dynamic features were the most important features in the model (TTP: 35.5%). In contrast, other radiomics features were the most useful for predicting the 1p/19q co-deletion (up to 14.5% of importance for the small zone low grey level emphasis).
Conclusion: F-FDOPA PET is an effective tool for the non-invasive prediction of glioma molecular parameters using a full set of amino-acid PET radiomics features. The contribution of each feature set shows the importance of systematically integrating dynamic acquisition for the prediction of the IDH mutations as well as developing the use of radiomics features in routine practice for the prediction the 1p/19q co-deletion.
Combined Omic Analyzes of Cerebral Thrombi: A New Molecular Approach to Identify Cardioembolic Stroke Origin
Background and purpose: The diagnosis of cardioembolic stroke can be challenging for patient management in secondary stroke prevention, particularly in the case of covert paroxysmal atrial fibrillation.
The molecular composition of a cerebral thrombus is related to its origin. Therefore, proteomic and metabolomic analyses of the retrieved thrombotic material should allow the identification of biomarkers or signatures to improve the etiological diagnosis of stroke.
Methods: In this pilot study, the proteome and metabolome of cerebral thrombi from atherothrombotic and cardioembolic stroke patients were studied according to ASCOD phenotyping (A: atherosclerosis; S: small-vessel disease; C: cardiac pathology; O: other causes; D: dissection), with the highest causality grade, from the ThrombiOMIC cohort (consecutive patients with stroke recanalized by mechanical thrombectomy in an acute phase).
Proteomic and metabolomic results were used separately or combined, and the obtained omic signatures were compared with classical cardioembolic stroke predictors using pairwise comparisons of the area under receiver operating characteristics.
Results: Among 59 patients of the ThrombiOMIC cohort, 34 patients with stroke showed a cardioembolic phenotype and 7 had an atherothrombotic phenotype.
Two thousand four hundred fifty-six proteins and 5019 molecular features of the cerebral thrombi were identified using untargeted proteomic and metabolomic approaches, respectively.
Area under receiver operating characteristics to predict the cardioembolic origin of stroke were calculated using the proteomic results (0.945 [95% CI, 0.871-1]), the metabolomic results (0.836 [95% CI, 0.714-0.958]), and combined signatures (0.996 [95% CI, 0.984-1]).
The diagnostic performance of the combined signatures was significantly higher than that of classical predictors such as the plasmatic BNP (B-type natriuretic peptide) level (area under receiver operating characteristics, 0.803 [95% CI, 0.629-0.976]).
Conclusions: The combined proteomic and metabolomic analyses of retrieved cerebral thrombi is a very promising molecular approach to predict the cardioembolic cause of stroke and to improve secondary stroke prevention strategies.
Description: A monoclonal antibody for detection of Acetyl P53 K382) from Human, Mouse, Rat. This Acetyl P53 K382) antibody is for IHC-P. It is affinity-purified from mouse ascites by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in mouse by using as an immunogen synthetic peptide of Acetyl P53 (K382)
Description: A monoclonal antibody for detection of Acetyl P53 K382) from Human, Mouse, Rat. This Acetyl P53 K382) antibody is for IHC-P. It is affinity-purified from mouse ascites by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in mouse by using as an immunogen synthetic peptide of Acetyl P53 (K382)
Description: A monoclonal antibody for detection of Acetyl P53 K382) from Human, Mouse, Rat. This Acetyl P53 K382) antibody is for IHC-P. It is affinity-purified from mouse ascites by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in mouse by using as an immunogen synthetic peptide of Acetyl P53 (K382)
Description: A Monoclonal antibody against Human TUBA2 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F10-2F2. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human CRX (monoclonal) (M03). The antibodies are raised in mouse and are from clone 2F12. This antibody is applicable in WB, E
Monoclonal SMO Antibody (monoclonal) (M10), Clone: 2F12
Description: A Monoclonal antibody against Human SMO (monoclonal) (M10). The antibodies are raised in mouse and are from clone 2F12. This antibody is applicable in E
Description: A Monoclonal antibody against Human CTSD (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F12-1B9. This antibody is applicable in WB and IHC, IP, E
Description: A Monoclonal antibody against Human CDC45L (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 3F11-1F3. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human YAP1 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 2F12. This antibody is applicable in WB, IHC and IF
Description: A Monoclonal antibody against Human PPOX (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F10. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human PFN2 (monoclonal) (M04). The antibodies are raised in mouse and are from clone 5F11. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human SALF (monoclonal) (M01). The antibodies are raised in mouse and are from clone 5F12. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human CDK4 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 4F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human CLK3 (monoclonal) (M05). The antibodies are raised in mouse and are from clone 1F10. This antibody is applicable in WB, IHC and IF
Description: A Monoclonal antibody against Human HEY1 (monoclonal) (M09). The antibodies are raised in mouse and are from clone 1F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human IL27 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F12. This antibody is applicable in WB, IP
Description: A Monoclonal antibody against Human JAK3 (monoclonal) (M05). The antibodies are raised in mouse and are from clone 3F10. This antibody is applicable in E
Description: A Monoclonal antibody against Human KLK8 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human AKT1 (monoclonal) (M09). The antibodies are raised in mouse and are from clone 6F11. This antibody is applicable in WB and IF
Description: A Monoclonal antibody against Human CES2 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 4F12. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human IDH2 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 5F11. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human HIP1 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F12. This antibody is applicable in WB and IHC, IP, E
Description: A Monoclonal antibody against Human SOX9 (monoclonal) (M04). The antibodies are raised in Mouse and are from clone 3F11. This antibody is applicable in WB, IHC and IF
Description: A Monoclonal antibody against Human NXT1 (monoclonal) (M08). The antibodies are raised in mouse and are from clone 4F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human CDSN (monoclonal) (M01). The antibodies are raised in mouse and are from clone 6F11. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human GDF7 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 4F10. This antibody is applicable in E
Description: A Monoclonal antibody against Human PSME2 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F11-1A3. This antibody is applicable in WB and IF
Description: A Monoclonal antibody against Human PCBP2 (monoclonal) (M07). The antibodies are raised in mouse and are from clone 5F12. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human EFNA5 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F12. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human POLA2 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human PRKCA (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F11. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human RAB3B (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F12. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human RASA3 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F11. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human SNAI2 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 2F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human TBX21 (monoclonal) (M10). The antibodies are raised in mouse and are from clone 2F10. This antibody is applicable in WB
Description: A Monoclonal antibody against Human TFDP3 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human TFDP3 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 3F11. This antibody is applicable in WB
Description: A Monoclonal antibody against Human TNNT3 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 1F12. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human WDR79 (monoclonal) (M04). The antibodies are raised in mouse and are from clone 1F12. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human FGF21 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F11. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human GSTA3 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F11. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human PDCL3 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F10. This antibody is applicable in WB
Description: A Monoclonal antibody against Human TSSK1 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 4F12. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human WDR77 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F10. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human PRTN3 (monoclonal) (M04). The antibodies are raised in mouse and are from clone 2F10. This antibody is applicable in E
Description: A Monoclonal antibody against Human STK33 (monoclonal) (M07). The antibodies are raised in mouse and are from clone 3F10. This antibody is applicable in WB, IHC and IF
Description: A Monoclonal antibody against Human STK33 (monoclonal) (M09). The antibodies are raised in mouse and are from clone 1F10. This antibody is applicable in WB and IF, IP
Description: A Monoclonal antibody against Human PYCRL (monoclonal) (M01). The antibodies are raised in mouse and are from clone 4F11. This antibody is applicable in WB and IF, IP, E
Description: A Monoclonal antibody against Human DEAF1 (monoclonal) (M05). The antibodies are raised in mouse and are from clone 3F11. This antibody is applicable in WB
Description: A Monoclonal antibody against Human FBXO6 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F10. This antibody is applicable in WB, IP
Description: A Monoclonal antibody against Human GATA2 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 2F12. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human NDST1 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 2F11. This antibody is applicable in WB
Description: A Monoclonal antibody against Human NSEP1 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 4F12. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human NUP62 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F12. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human NR0B1 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 1F10. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human NTNG2 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 4F11. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human CCL14 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F12. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human CFLAR (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F12. This antibody is applicable in WB, IHC and IF
Description: A Monoclonal antibody against Human HNF4A (monoclonal) (M05). The antibodies are raised in mouse and are from clone 1F12. This antibody is applicable in WB and IF
Description: A Monoclonal antibody against Human HTRA2 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 4F10. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human MTHFR (monoclonal) (M06). The antibodies are raised in mouse and are from clone 1F10. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human HOXD8 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 10F8. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human ITGB2 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 5F12. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human MKNK1 (monoclonal) (M14). The antibodies are raised in mouse and are from clone 2F12. This antibody is applicable in WB, IHC and IF
Description: A Monoclonal antibody against Human MKNK2 (monoclonal) (M04). The antibodies are raised in mouse and are from clone 4F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human MYBPH (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F11. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human NCOA4 (monoclonal) (M05). The antibodies are raised in mouse and are from clone 1F11. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human MAP3K4 (monoclonal) (M08). The antibodies are raised in mouse and are from clone 4F10. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human CXCL12 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 1F10. This antibody is applicable in E
Description: A Monoclonal antibody against Human RNF126 (monoclonal) (M04). The antibodies are raised in Mouse and are from clone 3F11. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human TRIM25 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 5F12. This antibody is applicable in WB and IF
Description: A Monoclonal antibody against Human FOXO1A (monoclonal) (M02). The antibodies are raised in Mouse and are from clone 1F11. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human CALML5 (monoclonal) (M16). The antibodies are raised in Mouse and are from clone 2F10. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human CDC14A (monoclonal) (M02). The antibodies are raised in mouse and are from clone 1F11. This antibody is applicable in WB and IF
Description: A Monoclonal antibody against Human FAM50A (monoclonal) (M02). The antibodies are raised in mouse and are from clone 5F10. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human FBXO42 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 2F10. This antibody is applicable in WB
Description: A Monoclonal antibody against Human TIMM8A (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F11. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human GSDMDC1 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F12-1B2. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human FASN (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 3F2-1F3. This antibody is applicable in WB, IHC and IF, IP
Description: A Monoclonal antibody against Human ORM1 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 2F9-1F10. This antibody is applicable in WB and IHC, IP, E
Description: A Monoclonal antibody against Human CEACAM1 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F10. This antibody is applicable in E
Description: Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12.
Description: Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12.
Description: Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12.
Description: A Monoclonal antibody against Human TNFRSF17 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F10. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human PNLIPRP2 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 4F10. This antibody is applicable in E
Description: A Monoclonal antibody against Human ADAMTS13 (monoclonal) (M06). The antibodies are raised in Mouse and are from clone 4F12. This antibody is applicable in E
Description: A Monoclonal antibody against Human FLJ23356 (monoclonal) (M03). The antibodies are raised in mouse and are from clone 6F10. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human FLJ20105 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F12-2B10. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human B2M (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F9-2C2. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human DSU (monoclonal) (M01). The antibodies are raised in mouse and are from clone 8F9-1B2. This antibody is applicable in WB, IP, E
Description: A Monoclonal antibody against Human PHB (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F4-2B2. This antibody is applicable in WB, IHC and IF, E
Description: A Monoclonal antibody against Human PPIA (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1F4-1B5. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human FRS2 (monoclonal) (M02). The antibodies are raised in Mouse and are from clone 1F7-1D6. This antibody is applicable in WB
Description: A Monoclonal antibody against Human FABP3 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 4F6-1D6. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human ANXA5 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F4-1A5. This antibody is applicable in WB, IHC and IF, IP
Description: A Monoclonal antibody against Human CCNL1 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F7-1C5. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human DNPEP (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F9-3A7. This antibody is applicable in WB and IF
Description: A Monoclonal antibody against Human STX1A (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F9-1C9. This antibody is applicable in WB
Description: A Monoclonal antibody against Human CAMKV (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F3-1A2. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human HLA-DMA (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F12-F11. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human RAB11A (monoclonal) (M01). The antibodies are raised in mouse and are from clone 1F7-2A8. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human NPEPL1 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 3F8-1A6. This antibody is applicable in WB and IF
Description: A Monoclonal antibody against Human SNAP23 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F5-3D4. This antibody is applicable in WB and IHC, IP, E
Description: A Monoclonal antibody against Human UNC119 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 2F9-2A9. This antibody is applicable in WB, IP
Description: A Monoclonal antibody against Human CTNNA3 (monoclonal) (M01). The antibodies are raised in mouse and are from clone 3F4-1B11. This antibody is applicable in WB
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177 Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort
Objective: To determine prospectively the efficacy profile of 2 activity regimens of Lu-PSMA therapy in patients with progressive metastatic castrate resistant prostate cancer (mCRPC): 6.0 vs 7.4 GBq.
Methods: RESIST-PC (NCT03042312) was a prospective multicenter phase 2 trial. Patients with progressive mCRPC after ≥1 novel androgen-axis drug, either chemotherapy naïve or post-chemotherapy, with sufficient bone marrow reserve, normal kidney function, and sufficient PSMA expression by PSMA PET were eligible.
Patients were randomized (1:1) into two activity groups (6.0 or 7.4 GBq) and received up to 4 cycles every 8 weeks. The primary endpoint was the efficacy of Lu-PSMA measured by the PSA response rate (RR) after 2 cycles (≥50% decline from baseline). Secondary endpoints included the PSA-RR (≥50% decline) at any time (best response), and overall survival (OS).
Results: The study was closed at enrollment of 71/200 planned patients because of sponsorship transfer. We report here the efficacy UCLA cohort results only (n = 43). The PSARRs after 2 cycles and at any time were 11/40 (28%, 95%CI 15-44), 6/13 (46%, 95%CI 19-75), 5/27 (19%, 95%CI 6-38), and 16/43 (37%, 95%CI 23-53), 7/14 (50%, 95%CI 23-77), 9/29 (31%, 95%CI 15-51) in the whole cohort, the 6.0 GBq and the 7.4 GBq groups, respectively (P = 0.12 and P = 0.31).
The median OS was 14.0 months (95%CI 10.1-17.9), 15.8 (95%CI 11.8-19.4), 13.5 (95%CI 10.0-17.0) in the whole cohort, the 6.0 GBq and the 7.4 GBq groups, respectively (P = 0.87). OS was longer in patients who experienced a PSA decline ≥50% at any time than those who did not: median: 20.8 vs. 10.8 months (P = 0.005).
Conclusion: In this prospective phase 2 trial of Lu-PSMA for mCRPC the median OS was 14 months. Despite the heterogeneous study population and the premature study termination, the efficacy profile of Lu-PSMA appeared to be favorable and comparable with both activity regimens (6.0 GBq vs. 7.4 GBq).
Results justify confirmation with real world data matched pair analysis and further clinical trials to refine and optimize the LuPSMA therapy administration scheme to improve tumor radiation dose delivery and efficacy.
Advances in understanding the molecular pathology of gynecological malignancies: the role and potential of RNA sequencing
For many years technological limitations restricted the progress of identifying the underlying genetic causes of gynecologicalcancers. However, during the past decade, high-throughput next-generation sequencing technologies have revolutionized cancer research. RNA sequencing has arisen as a very useful technique in expanding our understanding of genome changes in cancer.
Cancer is characterized by the accumulation of genetic alterations affecting genes, including substitutions, insertions, deletions, translocations, gene fusions, and alternative splicing. If these aberrant genes become transcribed, aberrations can be detected by RNA sequencing, which will also provide information on the transcript abundance revealing the expression levels of the aberrant genes.
RNA sequencing is considered the technique of choice when studying gene expression and identifying new RNA species. This is due to the quantitative and qualitative improvement that it has brought to transcriptome analysis, offering a resolution that allows research into different layers of transcriptome complexity.
It has also been successful in identifying biomarkers, fusion genes, tumor suppressors, and uncovering new targets responsible for drug resistance in gynecological cancers. To illustrate that we here review the role of RNA sequencing in studies that enhanced our understanding of the molecular pathology of gynecological cancers.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity. Known to inhibit cathepsin B, H, and L.
Description: A Monoclonal antibody against Human CST3 (monoclonal). The antibodies are raised in Mouse and are from clone 1H4. This antibody is applicable in WB
Description: A Monoclonal antibody against Human T. The antibodies are raised in Mouse and are from clone 394CT14.1.4. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human FYN. The antibodies are raised in Mouse and are from clone 1302CT390.118.237. This antibody is applicable in WB, FC, IHC-P, E
Monoclonal JUN antibody , Clone: 1306CT545.208.117
Description: A Monoclonal antibody against Human JUN . The antibodies are raised in Mouse and are from clone 1306CT545.208.117. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human VCP. The antibodies are raised in Mouse and are from clone 1344CT150.163.114. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human PHB. The antibodies are raised in Mouse and are from clone 1215CT487.109.106. This antibody is applicable in WB and IHC-P, E
Description: A Monoclonal antibody against Human SP1. The antibodies are raised in Mouse and are from clone 1326CT463.109.176. This antibody is applicable in WB, FC, IF, E
Description: A Monoclonal antibody against Human CD74. The antibodies are raised in Mouse and are from clone 1267CT820.116.140.154. This antibody is applicable in WB, FC, E
Description: A Monoclonal antibody against Human USP5. The antibodies are raised in Mouse and are from clone 1340CT704.170.140. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human RAC1. The antibodies are raised in Mouse and are from clone 1301CT276.121.104. This antibody is applicable in WB, FC, IHC-P, E
Description: A Monoclonal antibody against Human WNT4. The antibodies are raised in Mouse and are from clone 1698CT540.169.185. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human ATG5. The antibodies are raised in Mouse and are from clone 1358CT289.125.123. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human CDK5. The antibodies are raised in Mouse and are from clone 1321CT281.130.129. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human CDK5. The antibodies are raised in Mouse and are from clone 1321CT281.130.129. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human FLNA. The antibodies are raised in Mouse and are from clone 1273CT424.104.153. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human SRC. The antibodies are raised in Mouse and are from clone 1602CT774.225.92. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human CD138. The antibodies are raised in Mouse and are from clone 531CT15.4.1;531CT15.1.4. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human CREB1. The antibodies are raised in Mouse and are from clone 1335CT115.203.189. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human NFKB1. The antibodies are raised in Mouse and are from clone 1298CT792.105.117.133. This antibody is applicable in WB, FC, IHC-P, E
Description: A Monoclonal antibody against Human USP25. The antibodies are raised in Mouse and are from clone 1277CT376.106.171. This antibody is applicable in WB, E
Monoclonal AURKA Antibody, Clone: 1364CT291.108.155
Description: A Monoclonal antibody against Human AURKA . The antibodies are raised in Mouse and are from clone 1364CT291.108.155. This antibody is applicable in WB and IHC-P, E
Description: A Monoclonal antibody against Human APEX1. The antibodies are raised in Mouse and are from clone 1518CT337.123.86.269.232. This antibody is applicable in IF, IHC-P, WB, E
Description: A Monoclonal antibody against Human Stat3. The antibodies are raised in Mouse and are from clone 1200CT146.104.153. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human STAT3. The antibodies are raised in Mouse and are from clone 1200CT146.104.153. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human EPHA6. The antibodies are raised in Mouse and are from clone 1426CT591.205.91.119. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human PPARA. The antibodies are raised in Mouse and are from clone 1331CT894.186.143. This antibody is applicable in WB, FC, IF, IHC-P, E
Description: A Monoclonal antibody against Human CRYAB. The antibodies are raised in Mouse and are from clone 1329CT523.140.120. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human YWHAZ. The antibodies are raised in Mouse and are from clone 1314CT423.108.153.173.140. This antibody is applicable in WB and IF, E
Description: A Monoclonal antibody against Human CDK4. The antibodies are raised in Mouse and are from clone 1529CT850.162.73. This antibody is applicable in IHC-P, WB, E
Description: A Monoclonal antibody against Human VAV1. The antibodies are raised in Mouse and are from clone 1582CT802.383.58. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human MITF. The antibodies are raised in Mouse and are from clone 1607CT834.207.47. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human SUFU. The antibodies are raised in Mouse and are from clone 1783CT536.263.29. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human GLS2. The antibodies are raised in Mouse and are from clone 1758CT879.217.60. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human AKT2. The antibodies are raised in Mouse and are from clone 1623CT791.157.67.66. This antibody is applicable in WB, E
Description: A Monoclonal antibody against Human CDK5. The antibodies are raised in Mouse and are from clone 1552CT262.105.8. This antibody is applicable in IF, FC, IHC-P, WB, E
Description: A Monoclonal antibody against Human Musk. The antibodies are raised in Mouse and are from clone 1429CT456.173.44. This antibody is applicable in WB and IHC-P, E
Anti Beta-Estradiol Monoclonal Antibody (1977CT128.130.83)
